Observed and relative survival trends of lung cancer: A systematic review of population-based cancer registration data
- PMID: 37986711
- PMCID: PMC10788469
- DOI: 10.1111/1759-7714.15170
Observed and relative survival trends of lung cancer: A systematic review of population-based cancer registration data
Abstract
Background: Using the published survival statistics from cancer registration or population-based studies, we aimed to describe the global pattern and trend of lung cancer survival.
Methods: By searching SinoMed, PubMed, Web of Science, EMBASE, and SEER, all survival analyses from cancer registration or population-based studies of lung cancer were collected by the end of November 2022. The survival rates were extracted by sex, period, and country. The observed, relative, and net survival rates of lung cancer were applied to describe the pattern and time changes from the late 1990s to the early 21st century.
Results: Age-standardized 5-year relative/net survival rate of lung cancer was typically low, with 10%-20% for most regions. The highest age-standardized relative/net survival rate was observed in Japan (32.9%, 2010-2014), and the lowest was in India (3.7%, 2010-2014). In most countries, the five-year age-standardized relative/net survival rates of lung cancer were higher in females and younger people. The patients with adenocarcinoma had a better prognosis than other groups. In China, the highest 5-year overall relative/net survival rates were 27.90% and 31.62% in men and women in Jiangyin (2012-2013).
Conclusion: Over the past decades, the prognosis of lung cancer has gradually improved, but significant variations were also observed globally. Worldwide, a better prognosis of lung cancer can be observed in females and younger patients. It is essential to compare and evaluate the histological or stage-specific survival rates of lung cancer between different regions in the future.
Keywords: cancer registry; lung cancer; observed survival rate; population-based survival study; relative survival rate.
© 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Conflict of interest statement
All authors declare there are no conflicts of interest.
Figures
Similar articles
-
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23. Clin Orthop Relat Res. 2024. PMID: 39051924
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Trends of stomach cancer survival: A systematic review of survival rates from population-based cancer registration.J Dig Dis. 2022 Jan;23(1):22-32. doi: 10.1111/1751-2980.13070. Epub 2022 Jan 17. J Dig Dis. 2022. PMID: 34821032
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
-
Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?Clin Orthop Relat Res. 2024 Sep 1;482(9):1710-1721. doi: 10.1097/CORR.0000000000003030. Epub 2024 Mar 22. Clin Orthop Relat Res. 2024. PMID: 38517402
Cited by
-
Survival feature and trend of female breast cancer: A comprehensive review of survival analysis from cancer registration data.Breast. 2025 Feb;79:103862. doi: 10.1016/j.breast.2024.103862. Epub 2024 Dec 15. Breast. 2025. PMID: 39701013 Free PMC article. Review.
-
[Research Progress on the Role of GSDME-mediated Pyroptosis in the Treatment of Lung Cancer].Zhongguo Fei Ai Za Zhi. 2024 Jul 20;27(7):529-534. doi: 10.3779/j.issn.1009-3419.2024.106.17. Zhongguo Fei Ai Za Zhi. 2024. PMID: 39147707 Free PMC article. Review. Chinese.
-
The impact of depression on the quality of life of lung cancer patients undergoing chemotherapy: mediating effects of perceived social support.Front Psychiatry. 2025 Mar 21;16:1526217. doi: 10.3389/fpsyt.2025.1526217. eCollection 2025. Front Psychiatry. 2025. PMID: 40191118 Free PMC article.
-
Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review and meta-analysis.Front Immunol. 2025 Feb 6;16:1515027. doi: 10.3389/fimmu.2025.1515027. eCollection 2025. Front Immunol. 2025. PMID: 39981238 Free PMC article.
-
Innovative technologies and their clinical prospects for early lung cancer screening.Clin Exp Med. 2025 Jun 18;25(1):212. doi: 10.1007/s10238-025-01752-6. Clin Exp Med. 2025. PMID: 40533607 Free PMC article. Review.
References
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. - PubMed
-
- Cancer Hospital Chinese Academy of Medical Science . Chinese guideline for cancer registration. Beijing: People's Medical Publishing House (PMPH); 2016. p. 33–75.
-
- Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics. 1982;38(4):933–942. - PubMed
-
- Perme MP, Stare J, Estève J. On estimation in relative survival. Biometrics. 2012;68(1):113–120. - PubMed
-
- Hakulinen T, Seppä K, Lambert PC. Choosing the relative survival method for cancer survival estimation. Eur J Cancer. 2011;47(14):2202–2210. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous